Rivastigmine efficacy

Anticholinesterases E.g. physostigmine, tacrine, donepezil, metrifonate, huperzine A, eptastigmine, velnacrine, galantamine, rivastigmine Efficacy in early stages of AD... 

Corey-Bloom J, Anand R, Veach J, for the ENA 713 B352 Study Group (1998). A randomised trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild and moderately severe Alzheimer s disease. IntJGeriatrPsychopharmacolX, 55-65. 

Roskos LK, Boudinot ED Effects of dose and sex on the pharmacokinetics of piroxicam in the rat. Biopharm Drug Dispos 11 215-225, 1990 Rosier M, Anand R, Cici-Sain A, et al Efficacy and safety of rivastigmine in patients with Alzheimer s disease international randomized controlled trial. BMJ 318 633-640, 1999... 

Farlow M, Anand R, Messina J Jr, et al A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer s disease. Fur Neurol 44 231-241, 2000... 

Forette F, Anand R, Gharabawi G A phase II study in patients with Alzheimer s disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). Eur J Neurol 6 423 29, 1999... 

Grossberg G, Irwin P, Satlin A, et al Rivastigmine in Alzheimer s disease efficacy over two years. Am J Geriatr Psychiatry 12 420 31, 2004... 

McKeith I, Del Ser T, Spano P, et al Efficacy of rivastigmine in dementia with Lewy bodies a randomized, double-blind, placebo-controlled international study. Lancet 356 2031-2036, 2000... 

Wolfson, C., Oremus, M., Shukla, V., et al. Donepezil and rivastigmine in the treatment of Alzheimer s disease a best-evidence synthesis of the published data on their efficacy and cost-effectiveness. Clm. Ther. 24, 862-886, 2002. 

Rivastigmine is a pseudo-irreversible inhibitor of both acetyl and butyryl cholinesterases. Thus although the drug initially blocks the enzymes, it is metabolized by them thereby giving the drug a relatively short half-life. The top dose is often necessary to achieve therapeutic efficacy, at which dose the central and peripheral cholinergic side effects become apparent. 

Richard E, Walstra GJ, van Campen J, Vissers E, van Gool WA. [Rivastigmine for Alzheimer disease evaluation of preliminary results and of structured assessment of efficacy.] NedTijdschr Geneeskd 2002 146(l) 24-7. 

Bilikiewicz A, Opala G, Podemski R, Puzynski S, Lapin J, Soltys K, Ochudlo S, Barcikowska M, Pfeffer A, Bilinska M, Paradowski B, Parnowski T, Gabryelewicz T. An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer s disease in the community setting. Med Sci Monit 2002 8(2) PI9-15. 

Rivastigmine may interact with anticholinergic agents and the combination may decrease the efficacy of both... 

Abstract Alzheimer s disease is an illness that affects not only the pahents themselves but also those around them. Traditionally, cholinesterase inhibitors have been the first-line medications used in treating Alzheimer s disease. There are currently fom approved cholinesterase inhibitors tacrine, donepezil, rivastigmine, and galantamine. Each of these medications has a unique pharmacokinetic profile and mechanism of action. Researchers in the past 5-10 years have accumulated much data on the use of cholinesterase inhibitors. The use of cholinesterase inhibitors may preserve activities of daily living, slow progression of memory loss, and improve behavioral and cognitive symptoms associated with Alzheimer s and other related dementias. There is also some evidence to suggest that the efficacy in some cases may last more than a few years. In addition, there is some evidence that the use of cholinesterase inhibitors may be associated with reduction of caretaker stress. The use of cholinesterase inhibitor, however, does not drastically improve... 

---